Advertisement
Strategies & Technologies Driving Drug Discovery to Market
Subscribe to Drug Discovery & Development All
View Sample

FREE Email Newsletter

DDD Update

Daily news and top headlines for drug research professionals

Protein May Prevent Antibody-Mediated Transplant Rejection

July 31, 2014 8:40 am | News | Comments

A study presented at the 2014 World Transplant Congress evaluated the safety and efficacy of CSL Behring's C1 Inhibitor (C1-INH) concentrate in preventing antibody-mediated rejection following kidney transplants in highly sensitized patients. Read more...

TOPICS:

CHMP Has More Issues with Weight Loss Drug

July 31, 2014 8:34 am | News | Comments

Orexigen Therapeutics Inc. announced it has received the Day 180 List of Outstanding Issues from the European Medicines Agency's Committee for Medicinal Products for Human Use for the NB32 (naltrexone sustained release (SR) / bupropion SR) Marketing Authorization Application. Read more...

TOPICS:

Researchers ID New Malaria Vaccine Candidates

July 31, 2014 8:29 am | News | Comments

Researchers have discovered new vaccine targets that could help in the battle against malaria. Taking a new, large-scale approach to this search, researchers tested a library of proteins from the Plasmodium falciparum parasite with antibodies produced by the immune systems of a group of infected children. Read more...

TOPICS:
Advertisement

Peptide Generates New Insulin-Producing Cells

July 31, 2014 8:23 am | News | Comments

A new study by researchers at Sanford-Burnham Medical Research Institute has found that a peptide called caerulein can convert existing cells in the pancreas into those cells destroyed in type 1 diabetes—insulin-producing beta cells. Read more...

TOPICS:

Ebola Crisis Triggers Health Emergency

July 31, 2014 8:10 am | by Clarence Roy-Macaulay, Associated Press | News | Comments

The president of Sierra Leone declared a public health emergency as the Ebola crisis blamed for nearly 700 deaths deepened across West Africa, vowing to quarantine sick patients at home and conduct house-to-house searches for others who may have been exposed. Read more...

TOPICS:

Profectus BioSciences Snags $3.5M from NIH for HIV Vaccines

July 30, 2014 2:41 pm | News | Comments

Profectus BioSciences announced the award of two SBIR grants totaling $3.5 million from the Division of AIDS, National Institute of Allergy and Infectious Diseases (NIAID), National Institutes of Health (NIH). Read more...        

TOPICS:

FDA Approves Eylea for Third Indication

July 30, 2014 2:34 pm | News | Comments

Regeneron Pharmaceuticals Inc. announced that the FDA has approved Eylea (aflibercept) Injection for the treatment of Diabetic Macular Edema (DME). Read more...                          

TOPICS:

Treatment Combo Benefits Lung Cancer Patients

July 30, 2014 2:04 pm | News | Comments

A combination of the EGFR-targeted anticancer therapeutics Gilotrif and Erbitux yielded clinical responses in 29% of patients who had lung cancer harboring epidermal growth factor receptor mutations that had stopped responding to other inhibitors, according to new data. Read more...

TOPICS:
Advertisement

New Route to ID Bacterial Infection Drugs

July 30, 2014 1:41 pm | News | Comments

About 100 drugs already approved by the FDA for other purposes can also prevent the growth of certain bacterial pathogens inside human cells, including those that cause Legionnaires’ disease, brucellosis, and Mediterranean spotted fever. Read more... 

TOPICS:

Pfizer Buying Two Baxter Vaccines for $635M

July 30, 2014 1:26 pm | News | Comments

Pfizer will spend $635 million on two vaccines owned by Baxter International that are sold in a number of European countries and other locations outside of the U.S. Read more...                     

TOPICS:

Sage Licenses Gene Editing Tool from the Broad Institute

July 30, 2014 11:06 am | News | Comments

Sage Labs Inc., a leading provider of products, services and technologies in the field of genome engineering, announced that they have licensed CRISPR/Cas9 technology from the Broad Institute enabling them to use the CRISPR/Cas9 system to engineer cell and animal models for their clients as well as distribute validated CRISPR reagents. Read more...

TOPICS:

Diabetes Drugs Get Positive CHMP Opinions for CV Safety Updates

July 30, 2014 10:58 am | News | Comments

Takeda Pharmaceuticals International GmbH announced that the Committee for Medicinal Products for Human Use of the European Medicines Agency has issued positive opinions for updates to the Summary of Product Characteristics for Vipidia and the fixed-dose combination therapies Vipdomet and Incresync. Read more...

TOPICS:

AstraZeneca, Kyowa Hakko Kirin Partner on Immuno-Oncology Study

July 30, 2014 10:48 am | News | Comments

AstraZeneca announced that it has entered into a clinical study collaboration with Kyowa Hakko Kirin for a Phase 1/1b immuno-oncology study that will evaluate the safety and efficacy of two separate combinations of three investigational compounds in multiple solid tumors. Read more...

TOPICS:

European Commission Approves Eliquis for DVT, PE

July 30, 2014 10:37 am | News | Comments

Bristol-Myers Squibb Co. and Pfizer Inc. announced that the European Commission has approved Eliquis (apixaban) for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE), and the prevention of recurrent DVT and PE in adults. Read more...

TOPICS:

Researchers to Study BRCA1-Related Breast Cancer

July 30, 2014 10:26 am | by Ashley WennersHerron, Virginia Tech | News | Comments

Deborah Kelly and Zhi Sheng, assistant professors at the Virginia Tech Carilion Research Institute, recently received a grant from the Commonwealth Health Research Board to investigate hereditary breast cancer, an effort that may lead to new treatment approaches. Read more...

TOPICS:

Pages

X
You may login with either your assigned username or your e-mail address.
The password field is case sensitive.
Loading